PDCD1 and neoplasm: Indeed, subcutaneous CT26 tumor-bearing mice treated with AGuIX combined with 4 Gy-RT and anti-PD-1 presented decreased tumor volume and better survival compared to all other treatment groups, with 55% complete remission compared to 22% with RT and anti-PD-1, 11% with RT and AGuIX, and 0% with anti-PD-1 alone or with AGuIX.